Immunic reports pre-planned phase 1b interim analysis of imu-935 in psoriasis patients confounded by high placebo rate

– interim analysis revealed unexpected high placebo rate; two active arms did not separate from placebo – – no new safety signals observed for imu-935 in this trial – – company expects to continue imu-935 development in psoriasis – new york , oct. 20, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the outcome of a pre-planned interim group-level data analysis of its phase 1b clinical trial of imu-935 in patients with moderate-to-severe psoriasis. the overall trial is ongoing and remains blinded.
IMUX Ratings Summary
IMUX Quant Ranking